AzTrials
AzTrials

Dry Eye DiseaseNCT01775540

Systane Ultra Versus Maxidex Versus Saline

A study testing Systane Ultra, Saline solution and Maxidex in people with Dry Eye Disease, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study was to evaluate the healing action on the eye surface of the artificial tear Systane® ULTRA as compared to two other eyedrops: Maxidex and Saline solution. Dry eye disease leads to inflammation of the eye surface and treating dry eyes with artificial tears may lead to reduction in this inflammation and… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Dry Eye Disease
What is being tested?
Systane Ultra, Saline solution and Maxidex
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
36 participants
Where
1 siteUnited States
Study dates
May 2012to Oct 2012
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • A score of at least 15 on the Ocular Surface Discomfort Index (OSDI) symptom questionnaire.
  • Moderate vital staining, fluorescein (for corneal evaluation, 3-15 on the NEI scale) OR lissamine (for conjunctival evaluation, score of 2-6; temporal and nasal areas, each graded 0-3).
  • Willingness to use study drugs 4 times per day in both eyes.
  • Willingness to discontinue use of other artificial tear products.
  • Patient must provide written informed consent
  • Patient must understand the scope of the study including completion of worksheet and be willing to follow instructions and return for all required study visits
  • An intraocular pressure less than or equal to 22 mmHg in both eyes

Who cannot join

  • Contact Lens wearers
  • Pregnant and/or lactating women
  • Those with moderate to severe Meibomian Gland Disease i.e. plugging of 3 or more glands and/or pasty secretion from 3 or more glands or presence of obstructed glands out of a total of 10 glands evaluated in the central portion of the lower lid.
  • Uncontrolled systemic or ocular disease
  • Dry eye due to seasonal allergic conjunctivitis, contact lens related conjunctivitis or other acute or seasonal diagnosis.
  • Are monocular and/or legally blind
Show all 10Show fewer
  • Had ocular surgery or trauma within last six months
  • Participation in an ophthalmic drug or device research study within 30 days prior to entry in this study
  • Current use of any eye drops other than artificial tears
  • Use of Restasis within three months prior to entry in this study

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Mount Sinai School of Medicine

    New York, New York, 10029

Other trials in United States

About this study

Official title: Study to Evaluate the Ocular Surface Healing Action of the Artificial Tear Systane ULTRA Using Both Positive (Maxidex) and Negative (Saline Solution) Controls

This study was to evaluate the healing action on the eye surface of the artificial tear Systane® ULTRA as compared to two other eyedrops: Maxidex and Saline solution. Dry eye disease leads to inflammation of the eye surface and treating dry eyes with artificial tears may lead to reduction in this inflammation and improvement of symptoms and signs.

Read the detailed description

For all patients who present to the office with a history of dry eyes:

  1. Consent forms will be obtained from every patient. Informed consent will be discussed with the patient in detail. Every topic will be addressed separately. All risks, benefits, and alternatives will be discussed. Patient will be allowed to ask questions, and all questions will be answered. The assessment will be made after that conversation, whether or not the patient understood the consent as described above. Each subject will be allowed as much time as needed to review and sign the consent forms.
  2. All patients will be asked to fill out the Ocular Surface Discomfort Index (OSDI) questionnaire to ensure they meet the inclusion criteria. If patients score meets eligibility requirements a general and ocular history will be taken. (Time: 10 min)
  3. A pregnancy test will be given to all female subjects of child bearing age. A standard eye exam will be performed to rule out any other ocular pathology besides refractive error. This allows for confirmation that all study subjects have dry eye disease. Topical fluorescein and lissamine dye will be used to record staining on the cornea and conjunctiva of subjects as well as the tear film break-up time (TFBUT). Both of these dyes are used as standard-of-care in eye exams around the country. TFBUT will first be determined through application of sodium fluorescein onto the eye using DET strip. Following triplicate evaluation of TFBUT in each eye, ocular staining will be determined with liquid fluorescein and lissamine dyes administered in liquid form. (Time 15 min).
  4. Patients will be given Alcon questionnaires to fill out, inquiring about past treatments, daily symptoms and distress associated with their dry eye disease. (Time:15 minutes) This also serves as a waiting period for some of the dye to wash out.
  5. Using a graduated disposable 5 µl microcapillary tube (Wiretol-Micropipettes, Drummond Scientific Co., Broomall, PA, USA) up to 5 µl of tears / eye will be collected from the inferior temporal tear meniscus of each participant, without corneal anesthesia, taking care to ensure that the lid margin and corneal surface were not touched. A maximum of 5 minutes will be allowed per eye for collection of minimal 5 uL of tear. Tears will be immediately dispensed into pre-labeled Eppendorf tubes and placed on dry ice until transferred to -80oC for storage. (Time: 10 minutes)
  6. A technique known as Impression Cytology (IC) will be used to isolate epithelial cells from the conjunctiva. Anesthetic drops will be administered to each eye before the procedure. Blunted forceps are used to gently press a piece of filter paper against the patient's conjunctiva. The paper is gently lifted off, and sent to the Mount Sinai Laboratory for analyses. (Estimated collection time: 15 minutes). A total of 6 pieces per patient (3 pieces per eye) will be collected on each scheduled visit. For HLA-DR analysis, 2 pieces from each eye will be held at room temperature in a vial containing fixative until assay. The remaining 1 piece from each eye will be pooled together in one vial for RT-PCR assays in the following order: (1) immediately merged into a pre-labeled Eppendorf tube with 600 µL of TriZol Reagent; (2) Vortex for 30 seconds; (3) sealed with Saran Wrap; (4) transfer to -80C for storage until assay.
  7. Measurement of Intraocular pressure using Tonopen.
  8. As a part of the substudy we intend to treat patients with Systane ULTRA®, Maxidex, (both of which are FDA approved ophthalmic solutions), or the saline solution placebo. Subjects will be assigned to one of the three groups as per randomization sequence and the corresponding eye drop will be dispensed.
  9. The patient's response to treatment will be assessed after approximately 4 weeks (+/- 5 days) using the same diagnostic tests in order to assess the sensitivity of these diagnostic tests to detect the response to medical treatment of dry eye disease. In addition to baseline and 4 week visits, safety evaluations will be performed at a 2 week (+/- 5 days) visit. All the procedures done during the baseline visit will be repeated except pregnancy test, tear collection and impression cytology.
Conditions
Dry Eye Disease
Being tested
Systane Ultra, Saline solution, Maxidex
Keywords
Dry eye, Artificial tears, Ocular surface inflammation
Medical subject headings
Dry Eye Syndromes

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Systane UltraDrug

    Also called Artificial Tears

    Artificial tear Eyedrop, 1 drop used QID for 4 weeks

  • Saline solutionDrug

    Saline solution,1 drop used QID for 4 weeks

  • MaxidexDrug

    Also called Dexamethasone 0.1% eyedrop

    Eyedrop-1 drop QID for 4 weeks

Study groups in NCT01775540
Study groupRoleWhat they receive
Systane UltraExperimentalArtificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks
Receives: Drug: Systane Ultra
Saline solutionPlacebo comparatorSaline solution Eyedrop, 1 drop used QID for 4 weeks
Receives: Drug: Saline solution
MaxidexActive comparatorSteroid eyedrop, 1 drop QID for 4 weeks
Receives: Drug: Maxidex

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. OSDI score

    questionnaire pertaining to dry eye symptoms answered by patients

    Measured: at Baseline

  2. OSDI score

    questionnaire pertaining to dry eye symptoms answered by patients

    Measured: visit 2 (at 2 weeks)

  3. OSDI score

    questionnaire pertaining to dry eye symptoms answered by patients

    Measured: at visit 3 (at 4 weeks)

Secondary outcomes (21)
  1. Tear Film break up time

    Time taken for the first dry spot to appear in the tear film

    Measured: at Baseline

  2. Tear Film break up time

    Time taken for the first dry spot to appear in the tear film

    Measured: at visit 2 (at 2 weeks)

  3. Tear Film break up time

    Time taken for the first dry spot to appear in the tear film

    Measured: at visit 3 (at 4 weeks)

  4. Corneal Staining

    Grading of fluorescein staining of the cornea using a slit lamp and NEI grading scale

    Measured: at Baseline

  5. Corneal Staining

    Grading of fluorescein staining of the cornea using a slit lamp and NEI grading scale

    Measured: at visit 2 (at 2 weeks)

  6. Corneal Staining

    Grading of fluorescein staining of the cornea using a slit lamp and NEI grading scale

    Measured: at visit 3 (at 4 weeks)

  7. Conjunctival Staining

    Grading of Lissamine green staining of the conjunctiva using a slit lamp and NEI grading scale

    Measured: at Baseline

  8. Conjunctival Staining

    Grading of Lissamine green staining of the conjunctiva using a slit lamp and NEI grading scale

    Measured: at visit 2 (at 2 weeks)

  9. Conjunctival Staining

    Grading of Lissamine green staining of the conjunctiva using a slit lamp and NEI grading scale

    Measured: at visit 3 (at 4 weeks)

  10. Best corrected visual acuity

    BSCVA using ETDRS charts

    Measured: at Baseline

  11. Best corrected visual acuity

    BSCVA using ETDRS charts

    Measured: at visit 2 (at 2 weeks)

  12. Best corrected visual acuity

    BSCVA using ETDRS charts

    Measured: at visit 3 (at 4 weeks)

  13. Tear Cytokines

    Tear samples collected from both eyes using microcapillary tube. Samples analysed for inflammatory cytokines using Luminex bioassays

    Measured: At baseline

  14. Tear Cytokines

    Tear samples collected from both eyes using microcapillary tube. Samples analysed for inflammatory cytokines using Luminex bioassays

    Measured: At visit 3 (at 4 weeks)

  15. mRNA for HLA-DR

    Cell samples collected via impression cytology and analysed for mRNA expression via flowcytometer

    Measured: At baseline

  16. mRNA for HLA-DR

    Cell samples collected via impression cytology and analysed for mRNA expression via flowcytometer

    Measured: At visit 3 (at 4 weeks)

  17. HLA-DR expression

    Cell samples collected via impression cytology and analysed for HLA-DR expression via flowcytometer

    Measured: At baseline

  18. HLA-DR expression

    Cell samples collected via impression cytology and analysed for HLA-DR expression via flowcytometer

    Measured: At visit 3 (at 4 weeks)

  19. IDEEL questionnaire

    questionnaire pertaining to dry eye symptoms, quality of life, and treatment answered by patients

    Measured: At baseline

  20. IDEEL questionnaire

    questionnaire pertaining to dry eye symptoms, quality of life, and treatment answered by patients

    Measured: At visit 2 (at 2 weeks)

  21. IDEEL questionnaire

    questionnaire pertaining to dry eye symptoms, quality of life, and treatment answered by patients

    Measured: At visit 3 (at 4 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jan 2013 (estimated)
  2. Study startMay 2012
  3. Primary completionOct 2012
  4. Study completionOct 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01775540
Sponsor's protocol ID
GCO 11-1230
Status last verified
Jan 2013
First submitted
7 Dec 2012
Last updated
25 Jan 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Systane Ultra, Saline solution and Maxidex in people with Dry Eye Disease, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

OSDI score (time frame: at Baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2013.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in